Market News AIOpen the app

RYTM stock news · Rhythm Pharmaceuticals

Stories about Rhythm Pharmaceuticals (RYTM) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for RYTM

Follow Rhythm Pharmaceuticals (RYTM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RYTM
Free on the App Store and Google Play, or on the web.
  1. Nov 3, 2026, 9:35 AM ET · Results

    Rhythm Pharmaceuticals shared its Q3 2026 earnings, showing $92 million in sales from the launch of Imcivree.

    Good for RYTM

    Rhythm reported $92 million in quarterly sales, launched Imcivree in Japan, and amended a deal with $350 million in payments over 4 years. Demand and lower royalties make the update favorable.

  2. Aug 12, 2026, 1:27 PM ET · Market

    Rhythm Pharmaceuticals' shares rise on Wednesday following expanded marketing approval for Imcivree by the UK's regulatory agency.

    Good for RYTM

    Rhythm Pharmaceuticals' stock is trading higher following the UK's Medicines and Healthcare products Regulatory Agency's expansion of marketing authorization for Imcivree. This regulatory approval allows the drug to treat obesity in both adults and children with acquired hypothalamic obesity, which is expected to enhance the company's market potential and drive sales growth.